Daewoong Pharmaceutical and Daewoong Therapeutics have announced a major breakthrough in drug delivery technology. Their semaglutide microneedle patch has achieved over 80% relative bioavailability in comparison to injectable obesity therapy, setting a new global benchmark. This result far exceeds the 30% bioavailability typically seen in existing microneedle patches. The success of this patch could change the game by addressing both the pain of injections and the low efficiency of oral formulations.
Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability
-
Flamengo and PSG have faced each other three times; check out their record
-
Indonesia Open Footgolf Tournament: Comedian Oki Rengga Admits Addiction, Wants to Become a Professional Athlete
-
Shameful Incident in Punjab! Landlord Rolls Tenant’s Daughter
-
Virgil van Dijk Expresses Desire for Mohamed Salah to Stay at Liverpool
Deixe um comentário